Redeye views BioInvent’s SEK 487m directed issue very positively, as it should allow for continued clinical development of BI-1206 as well as bringing additional promising projects into the clinic, thus strengthening the pipeline prospects. We believe the terms are favourable and expect a clear positive reaction. Our base case of SEK 2.5 is under review for an upgrade.